Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Plasminogen
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Kedrion
Deal Size : $17.0 million
Deal Type : Acquisition
Kedrion Biopharma Grows in North America As it Completes Acquisition of Prometic
Details :
Product Name : Ryplazim
Product Type : Protein
Upfront Cash : Undisclosed
October 18, 2021
Lead Product(s) : Plasminogen
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Kedrion
Deal Size : $17.0 million
Deal Type : Acquisition